Latest Teriparatide Stories
SILVER SPRING, Md., June 1 /PRNewswire-USNewswire/ -- The U.S.
For best results, patient selection, correct indications, optimal medical treatment needed, according to a study of nearly 1,500 patients over seven years
WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's effect on reduction of new hip fractures is the attribute that most influences U.S.
Endocrinologists at the University of Pittsburgh School of Medicine and UPMC are launching a human trial of a new drug that their research indicates holds great promise for building bones weakened by osteoporosis.
A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone.
DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis.
An existing osteoporosis drug is the first ever found to prevent cartilage loss from osteoarthritis following injury to a joint, and may also regenerate some cartilage that has been lost to osteoarthritis.
Studies suggest that a first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments and could soon add a more expensive but easier option to the booming market.
CAMBRIDGE, Mass., Aug.
INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S.